|
|
|
|
|
|
Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Pharmaceutical Company Outlook to 2012: Strategic Analysis
Datamonitor
Based on an analysis of 43 companies and 1,200+ products, we forecast that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.
Scope
Strategic Analysis of the Sales Outlook to 2012 for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Quantitative analysis of the revenue balance of launches and expiries for each peer set member to 2012
Assessment of current and forecast 2012 therapy area sales and molecule type focus for each peer set member
Highlights
Faced with failing growth, Big Pharma is expected to pursue strategic options including operational cost efficiencies, M&A with other Big Pharma companies, biotech, Mid Pharma CNS players and/or generics manufacturers and acquisitional moves outside of 'pharma space' to increase presence in medical devices, diagnostics and consumer healthcare.
Reasons to Purchase
Understand the strategic motives behind the recent wave of Big Pharma acquisitions of monoclonal antibody companies
Identify the rare examples of promising high growth CNS products located in the Mid Pharma peer set
Learn how biotech faces slowing growth momentum due to commercial pressures on therapeutic proteins.
160 pages
Publication Date : Dec 2007
|
|
|
|
|
|
|
Pharmaceutical Supply Chain Strategies
Ideally drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible, however in practice it can be a highly circuitous one that includes several intermediaries before reaching a pharmacy. (MORE)
|
|
|
 |
|
|
Strategic Alliances in World Pharma and Biotech Markets
In the last decade or so, strategic alliances and partnerships among pharmaceutical and biotech companies have doubled to around 700 per year per sector, although most of this increase came in the early years.
Regardless of its size, every pharma or biotech company has certain limitations in their own research although usually they have enough capacity in development to bring new compounds to the market very effectively.
However, on a number of occasions, the inhouse development capacity may get prioritized in favor of other products within the company’s portfolio.
A product may also be facing competition internally from other projects, not necessarily similar compounds, but perhaps programs better aligned to the overall R&D activities. (MORE)
|
|
|
|
|
|
|
|
|
|
|
)